Colorectal cancer (CRC) is a major global health challenge as the third leading cause for cancer related mortalities worldwide. Despite advances in therapeutic strategies, the five-year survival rate for CRC patients has remained the same over time due to the fact that patients are often diagnosed in advanced metastatic stages. Drug resistance is another common reason for poor prognosis. Researchers are now developing advanced therapeutic strategies such as immunotherapy, targeted therapy, and combination nanotechnology for drug delivery. In addition, the identification of new biomarkers will potentiate early stage diagnosis. This book is the first of three volumes on recent developments in colorectal diagnosis and therapy. Each volume can be read on its own, or together. Each volume focuses on different novel therapeutic advances, biomarkers, and identifies therapeutic targets for treatment. Written by leading international experts in the field, coverage also addresses the role of diet habits and lifestyle in reducing gastrointestinal disorders and incidence of CRC. Chapters discuss current and future diagnostic and therapeutic options for colorectal cancer patients, focusing on immunotherapeutic, nanomedicine, biomarkers, and dietary factors for the effective management of colon cancer.

Colorectal cancer (CRC) is a major global health challenge as the third leading cause for cancer related mortalities worldwide. Despite advances in therapeutic strategies, the five-year survival rate for CRC patients has remained the same over time due to the fact that patients are often diagnosed in advanced metastatic stages. Drug resistance is another common reason for poor prognosis. Researchers are now developing advanced therapeutic strategies such as immunotherapy, targeted therapy, and combination nanotechnology for drug delivery. In addition, the identification of new biomarkers will potentiate early stage diagnosis. This book is the second of three volumes on recent developments in colorectal diagnosis and therapy. Each volume can be read on its own, or together. Each volume focuses on different novel therapeutic advances, biomarkers, and identifies therapeutic targets for treatment. Written by leading international experts in the field, coverage addresses the role of diet habits and lifestyle in reducing gastrointestinal disorders and incidence of CRC. Chapters discuss current and future diagnostic and therapeutic options for colorectal cancer patients, focusing on immunotherapeutics, nanomedicine, biomarkers, and dietary factors for the effective management of colon cancer.

This book provides an up-to-date overview of gastrointestinal malignancies, including prevention, early detection, intervention, and life-extending therapeutics. It also assesses various biomarkers used for diagnostics, prognostics and prediction of response to chemoresistance. Further, it discusses the latest trends in the use of small-molecule targeted therapies and immunotherapies as single agents or combination with other treatments. Since resistance to radiation and chemotherapy contribute to the high recurrence and poor survival rates, improving the outcome for GI malignancies is dependent on the introduction of new biomarkers and therapeutic agents. Lastly, the book systematically investigates novel theranostics approaches using nanotechnology for the detection, diagnosis, and personalized treatment of GI malignancies.

Colorectal cancer (CRC) is a major global health challenge as the third leading cause for cancer related mortalities worldwide. Despite advances in therapeutic strategies, the five-year survival rate for CRC patients has remained the same over time due to the fact that patients are often diagnosed in advanced metastatic stages. Drug resistance is another common reason for poor prognosis. Researchers are now developing advanced therapeutic strategies such as immunotherapy, targeted therapy, and combination nanotechnology for drug delivery. In addition, the identification of new biomarkers will potentiate early stage diagnosis.This book is the third of three volumes on recent developments in colorectal diagnosis and therapy. Each volume can be read on its own, or together. Each volume focuses on different novel therapeutic advances, biomarkers, and identifies therapeutic targets for treatment. Written by leading international experts in the field, coverage addresses the role of diet habits and lifestyle in reducing gastrointestinal disorders and incidence of CRC. Chapters discuss current and future diagnostic and therapeutic options for colorectal cancer patients, focusing on immunotherapeutics, nanomedicine, biomarkers, and dietary factors for the effective management of colon cancer.

This book reviews current immunotherapeutic strategies for gastrointestinal (GI) malignancies, including immune composition, immune checkpoint inhibitors, cell therapy, and peptide vaccines used to protect against esophageal, gastric, hepato-biliary, pancreatic and colorectal cancers. It also discusses the current challenges of using immunotherapy for the treatment of gastrointestinal malignancies. The book reviews highly sensitive and specific immunomarkers for the detection of GI malignancies, and examines therapeutic vaccines and the major cytokines involved in GI immunotherapy, as well as their basic biology and clinical applications. In closing, the book explores various aspects of computational biology for the detection and treatment of GI malignancies.

Immune landscape of pancreatic cancer development and drug resistance explores the advances in immune-based therapies aimed at harnessing the power of the immune system against pancreatic cancer and rewiring tumor microenvironments to eradicate pancreatic cells. With a strong focus on the development of therapeutic methods to improve the survival rates of pancreatic cancer, this book also shows the latest trends in immune targeted approaches for pancreatic cancer treatment. In 12 chapters Immune landscape of pancreatic cancer development and drug resistance discusses the current understanding of PC development and its various mutational and immune features and explore some of the new immune-based therapies aimed at targeting pancreatic cancer. It covers the urgent need for developing novel therapeutic modalities and aims at delineating future fields and avenues of research in pancreatic cancer treatment. The book provides the reader with an updated understanding of the immune landscape of PC and an all-encompassing overview of the latest trends in immune targeted approaches for PC treatment. This book is a valuable resource for health professionals, scientists and researchers, students, and all those who wish to broaden their knowledge of the advances in immunotherapy in pancreatic cancer.

This book provides an up-to-date overview of gastrointestinal malignancies, including prevention, early detection, intervention, and life-extending therapeutics. It also assesses various biomarkers used for diagnostics, prognostics and prediction of response to chemoresistance. Further, it discusses the latest trends in the use of small-molecule targeted therapies and immunotherapies as single agents or combination with other treatments. Since resistance to radiation and chemotherapy contribute to the high recurrence and poor survival rates, improving the outcome for GI malignancies is dependent on the introduction of new biomarkers and therapeutic agents. Lastly, the book systematically investigates novel theranostics approaches using nanotechnology for the detection, diagnosis, and personalized treatment of GI malignancies.

Gastrointestinal (GI) malignancies account for a large portion of cancers worldwide. Although incidence of esophageal, gastric, and colorectal cancers has decreased in recent years, pancreatic and liver cancer have increased. The mainstay of GI cancer therapy is chemoradiation and surgery. Despite significant medical advancements, diagnosis and therapy for GI cancers remain challenging due to tumor cell resistance to chemoradiotherapy. The tumor's increased cell signalling due to excessive transcription factor activation and increased stellate cell activity leads to collagen deposition formation of a dense stroma around the tumor, which prevents drugs from reaching the malignant cells. This leads to tumor chemoresistance.To circumvent these difficulties, drug therapy targeting the tumor's specific microenvironment and the additive anticancer effect of phytochemicals can allow for more effective treatment. This volume will be the first on the market on the topic of phytochemicals and their effect on the tumor microenvironment (TME). TME is an emerging area of research and the book will be a welcome introductory addition to the field.

Theranostics and Precision Medicine for the Management of Hepatocellular Carcinoma, Volume Two: Diagnosis, Therapeutic Targets and Molecular Mechanisms for Hepatocellular Carcinoma Progression provides comprehensive information about ongoing research and clinical data surrounding liver cancer. The book presents detailed descriptions about diagnostics and therapeutic options for easy understanding, with a focus on precision medicine approaches to improve treatment outcomes. The volume discusses topics such as computational approaches for identification of biomarkers, enzymes and pathways of HCC, circulating and epigenetic biomarkers, drug resistance, metabolic pathways, and small molecule-target therapies. In addition, it discusses immunotherapies, immune check point inhibitors and nanotechnology-based therapies. This book is a valuable resource for cancer researchers, oncologists, graduate students, hepathologists and members of biomedical research who need to understand more about liver cancer to apply in their research work or clinical setting.

Theranostics and Precision Medicine for the Management of Hepatocellular Carcinoma, Volume One: Biology and Pathophysiology provides comprehensive information about ongoing research and clinical data surrounding liver cancer. The book presents detailed descriptions about diagnostics and therapeutic options for easy understanding, with a focus on precision medicine approaches to improve treatment outcomes. This volume discusses topics such as tumor microenvironment in hepatocellular carcinoma, endoplasmic reticulum stress and unfolded protein response, effects of cirrhosis and hepatitis on the prognosis of HCC, mitochondrial metabolism, next generation sequencing, and telomerase. In addition, it discusses exosomes role in HCC progression, metastasis and chemokines. This is a valuable resource for cancer researchers, oncologists, graduate students, hepathologists and members of biomedical research who need to understand more about liver cancer for their research work or clinical setting.

Theranostics and Precision Medicine for the Management of Hepatocellular Carcinoma: Translational and Clinical Outcomes, Volume Three provides comprehensive information about ongoing research and clinical data on liver cancer. The book presents detailed descriptions about diagnostics and therapeutic options for easy understanding, with a focus on precision medicine approaches to improve treatment outcomes. This updated volume discusses topics such as clinical and safety assessment of HCC patients, liver transplantation as a therapeutic option, immunotherapy interventions, and image-based surveillance. In addition, it discusses immunohistology of HCC-enabled precision medicine and artificial intelligence for hepatocellular carcinomas. This is a valuable resource for cancer researchers, oncologists, graduate students, hepathologists and members of biomedical research who need to understand more about liver cancer to apply in their research work or clinical setting.

This book comprehensively describes the association between metabolic syndrome and pancreatic cancer progression, and the mechanism of action and target definition with a view to drug discovery. Metabolic syndrome, which includes adnominal obesity, hypertension, dyslipidemia, and hyperglycemia, has recently been shown to play an important role in the etiology and progression of various cancers. Further, obesity and diabetes have been associated with an increased incidence of gastric cancers. The book reviews the key biological mechanisms underlying the association between metabolic dysregulation, including obesity-associated enhancement of growth factor signaling, inflammation, and perturbation in pancreatic cancer cell growth and metastasis. It also illustrates the role of the inflammatory signaling pathway in metabolic diseases as well as tumor growth and explores the potential of these pathways as the rational targets for pancreatic cancer therapy. Lastly, the book offers a comprehensive description of the challenges associated with diabetes and pancreatic cancer therapy.

This book comprehensively describes the association between metabolic syndrome and pancreatic cancer progression, and the mechanism of action and target definition with a view to drug discovery. Metabolic syndrome, which includes adnominal obesity, hypertension, dyslipidemia, and hyperglycemia, has recently been shown to play an important role in the etiology and progression of various cancers. Further, obesity and diabetes have been associated with an increased incidence of gastric cancers. The book reviews the key biological mechanisms underlying the association between metabolic dysregulation, including obesity-associated enhancement of growth factor signaling, inflammation, and perturbation in pancreatic cancer cell growth and metastasis. It also illustrates the role of the inflammatory signaling pathway in metabolic diseases as well as tumor growth and explores the potential of these pathways as the rational targets for pancreatic cancer therapy. Lastly, the book offers a comprehensive description of the challenges associated with diabetes and pancreatic cancer therapy.

Theranostic Approach for Pancreatic Cancer modulates the biologic properties of stroma in pancreatic cancer by targeting the several chemotherapy resistance mechanisms to impede their malignant property through introducing new strategies and drugs for tackling the disease. It brings information about ongoing research as well as clinical data about pancreatic cancer and provides detailed descriptions about diagnostic and therapeutic options for easy understanding. The book discusses several topics related to pancreatic cancer, such as stem cells, drug resistance and pancreatic tumor microenvironment, the latest developments in chemotherapy for metastatic cancer and chemoprevention, and epigenome as a therapeutic strategy. Additionally, it encompasses a discussion on theranostic clinical applications for personalized treatment and management of pancreatic cancer. The book is a valuable resource for cancer researchers, oncologists, and several members of the biomedical field who need to understand more about the diagnosis and treatment of pancreatic cancer.

Breaking Tolerance to Pancreatic Cancer Unresponsiveness to Chemotherapy edited by Dr. Nagaraju, PhD., DSc. focuses on overriding the resistance from chemotherapeutic drugs with a broader range of treatment options. It particularly focuses on stroma, tumor microenvironment, stem cells, stellate cells, transcription factors, growth factors, and important signaling pathways. This volume discusses topics such as pancreatic cancer biology, current therapeutic options, EMT, chemotherapy resistance mechanisms, and genetic manipulations and natural products to enhance the sensitivity of pancreatic cancer to chemotherapy. Additionally, it discusses small targeted molecules and pancreatic cancer trials, and nanotechnology-based drug delivery. Breaking Tolerance to Pancreatic Cancer Unresponsiveness to Chemotherapy is a valuable source for researchers and advanced students in cancer and oncology as well as clinicians and medical students who are interested in learning more about ways to break pancreatic cancer resistance to chemotherapy.

A Theranostic and Precision Medicine Approach for Female-Specific Cancers provides information regarding ongoing research and clinical data surrounding female specific cancers (breast, cervical, ovarian and endometrial cancers). The book encompasses detailed descriptions about diagnostics and therapeutic options for easy understanding, focusing on the subject matter with a broader range of treatment options. In addition, it explores new theranostics, i.e., diagnostic, therapeutic and precision medicine strategies currently being developed for FSCs. This book is a valuable resource for cancer researchers, clinicians, graduate students and other members of biomedical field who need to understand the most recent and promising approaches to manage FSCs.